Integrated Network Pharmacology and in vivo Experimental Validation Approach to Explore the Potential Antioxidant Effects of Annao Pingchong Decoction in Intracerebral Hemorrhage Rats
Xuqing Zhou,Xu Wang,Jiaqi Li,Mengxue Zhang,Yi Yang,Shihui Lei,Ying He,Hua Yang,Desheng Zhou,Chun Guo
DOI: https://doi.org/10.2147/dddt.s439873
IF: 4.3188
2024-03-05
Drug Design Development and Therapy
Abstract:Xuqing Zhou, 1, 2, &ast Xu Wang, 1, 2, &ast Jiaqi Li, 3, &ast Mengxue Zhang, 4 Yi Yang, 1 Shihui Lei, 1 Ying He, 3 Hua Yang, 3 Desheng Zhou, 4 Chun Guo 1, 2 1 Experiment Center of Medical Innovation, the First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, People's Republic of China; 2 The First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410007, People's Republic of China; 3 College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha, Hunan, 410128, People's Republic of China; 4 Department of Neurology, the First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chun Guo, Email Background: Annao Pingchong decoction (ANPCD) is a traditional Chinese decoction which has definite effects on treating intracerebral hemorrhage (ICH) validated through clinical and experimental studies. However, the impact of ANPCD on oxidative stress (OS) after ICH remains unclear and is worth further investigating. Aim: To investigate whether the therapeutic effects of ANPCD on ICH are related to alleviating OS damage and seek potential targets for its antioxidant effects. Materials and Methods: The therapeutic candidate genes of ANPCD on ICH were identified through a comparison of the target genes of ANPCD, target genes of ICH and differentially expressed genes (DEGs). Protein–protein interaction (PPI) network analysis and functional enrichment analysis were combined with targets-related literature to select suitable antioxidant targets. The affinity between ANPCD and the selected target was verified using macromolecular docking. Subsequently, the effects of ANPCD on OS and the selected target were further investigated through in vivo experiments. Results: Forty-eight candidate genes were screened, in which silent information regulator sirtuin 1 (SIRT1) is one of the core genes that has antioxidant effects and ICH significantly affected its expression. The good affinity between 6 compounds of ANPCD and SIRT1 was also demonstrated by macromolecular docking. The results of in vivo experiments demonstrated that ANPCD significantly decreased modified neurological severity scoring (mNSS) scores and serum MDA and 8-OHdG content in ICH rats, while significantly increasing serum SOD and CAT activity, complicated with the up-regulation of ANPCD on SIRT1, FOXO1, PGC-1α and Nrf2. Furthermore, ANPCD significantly decreased the apoptosis rate and the expression of apoptosis-related proteins (P53, cytochrome c and caspase-3). Conclusion: ANPCD alleviates OS damage and apoptosis after ICH in rats. As a potential therapeutic target, SIRT1 can be effectively regulated by ANPCD, as are its downstream proteins. Keywords: intracerebral hemorrhage, Annao Pingchong decoction, oxidative stress, network pharmacology, vivo experiments, SIRT1 Graphical Intracerebral hemorrhage (ICH) is a cerebrovascular disease that has significantly affected people's lives worldwide due to its high incidence and mortality and poor outcome. 1–3 The complexity of ICH arises from diverse causes and the interaction of multiple pathological mechanisms. Various factors contribute to ICH formation, including hypertension, smooth muscle cell degeneration, cerebral amyloid angiopathy, oral anticoagulant use, vascular malformations, and hypercholesterolemia. 4 The development of ICH is driven by interconnected pathological mechanisms such as oxidative stress (OS), inflammation, brain edema, and neuronal apoptosis, which progressively exacerbate brain injury. 5,6 Currently, the treatment of ICH predominantly focuses on managing blood pressure, utilizing anticoagulants and surgery to prevent hematoma expansion, and mitigating risk factors to prevent secondary brain injury. However, there is still insufficient evidence that substantiates the significant improvements in mortality and neurological outcomes following ICH with these treatment modalities. 7 Thus, further research is necessary to identify new targets and develop more effective treatment options for ICH. OS, characterized by excessive accumulation of reactive oxygen species (ROS), plays an important role in aggravating neuronal cell death and neurological dysfunction after ICH. 6 The excessive ROS directly impairs cellular structures and induces cell death through the oxidation of lipids and DNA, which -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal